@Article{biocell.2021.013496,
AUTHOR = {JUNQI GUO, YUN YANG, WEI ZHAO, ZHONGHAI YAN, XIA YANG, YUNFEI YAN, RUIMIN HAO, JINXIA HU, FEI JIAO},
TITLE = {MiR-16-5p plays an inhibitory role in human non-small cell lung cancer through Fermitin family member 2},
JOURNAL = {BIOCELL},
VOLUME = {45},
YEAR = {2021},
NUMBER = {3},
PAGES = {627--638},
URL = {http://www.techscience.com/biocell/v45n3/41688},
ISSN = {1667-5746},
ABSTRACT = {Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer
progression. However, the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer
(NSCLC) are not to be well studied. Here, we validated that the expression of miR-16-5p was decreased significantly
in NSCLC samples and cell lines. The correlation between the clinicopathological features of NSCLC and the miR-16-
5p expression showed that the expression of miR-16-5p in non-small cell lung cancer was linked with the advanced
TNM stage, positive lymph node metastasis, with short overall survival (OS). Also, a negative correlation between
miR-16-5p and Fermitin family member 2 (FERMT2) was observed, implying there may be a potential link about
their regulation. The hypothesis was further confirmed by in-silico analysis and dual-luciferase reporter assay.
Moreover, we demonstrated that the transfections of miR-16-5p mimics could alter some biological characteristics of
NSCLC cells remarkably accomplished by the expression variance of FERMT2 <i>in vitro</i> and <i>in vivo</i> assays. Summarily,
this study demonstrated that miR-16-5p, as a tumor suppression factor in NSCLC by targeting FERMT2, could serve
as one promising biomarker in the prediction for NSCLC patients.},
DOI = {10.32604/biocell.2021.013496}
}